Pfizer CEO Bourla Suggests Pharma Tariffs Will Focus on US Adversaries, Not Allies

Pfizer CEO Albert Bourla expressed "cautious optimism" that upcoming pharmaceutical tariffs will target countries posing actual national security risks rather than US allies4
The White House is conducting a Section 232 investigation into pharmaceutical products to evaluate whether foreign dependence on drugs and APIs constitutes a national security risk5
Pfizer has already factored $150 million in tariff-related costs into its 2025 financial guidance, according to CFO David Denton25
Bourla stated that tariff uncertainty is preventing "tremendous investments" in the US for both R&D and manufacturing2
If tariffs are implemented, Pfizer plans to mitigate impacts by transferring production from overseas facilities to its 13 existing US manufacturing sites2
Despite facing an 8% drop in sales during the first quarter, Bourla remains confident about Pfizer's ability to navigate potential tariff challenges3
The company is maintaining its 2025 financial forecasts for now but warned it cannot predict the full impact of potential tariffs or trade policy changes1
Bourla emphasized that countries generally don't want critical medicines produced in nations experiencing high geopolitical tensions5

Sources:

1. https://www.biopharmadive.com/news/pfizer-pharma-tariffs-232-bourla-optimistic/746583/

2. https://www.businessinsider.com/pfizer-ceo-trump-tariffs-stopping-tremendous-investments-in-us-2025-4

3. https://firstwordpharma.com/story/5955108

4. https://endpts.com/pfizers-bourla-projects-confidence-that-tariffs-will-focus-on-us-adversaries/

5. https://www.ainvest.com/news/pfizer-tariff-dilemma-navigating-trade-barriers-shifting-landscape-2504/